Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort study
Authors' conclusion
Pneumococcal vaccine uptake in inflammatory rheumatic diseases is low, especially in younger patients and those not on biologic therapy.
Study context
- Population
- Individuals with RA, PsA and axSpA, single centre in the UK, October–December 2023
- Participants
- 906 individuals
- Outcome
- Vaccine uptake rates (pneumococcal, influenza, Covid-19) and factors determining uptake
Methodological detailssingle-centre, logistic regression adjusted for demographic and clinical factors
- Single-centre
- Logistic regression adjusted for demographic and clinical factors
Main finding
As reported in the abstract
Pneumococcal vaccine uptake
Received a pneumococcal vaccine
316
35%
Influenza vaccine uptake
63%
Covid-19 vaccine uptake
87%
Observational data: associations, not effects.
Further findings
Predictors of pneumococcal vaccine uptake
- OR for age ≥ 65 years
- 1.67 (95% CI: 1.21, 2.29)
- OR for biologic therapy
- 1.81 (95% CI: 1.33, 2.47)
- OR for additional JCVI Green Book indicators
- 1.67 (95% CI: 1.19, 2.33)
Original publication
Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort study. Rheumatology (Oxford). Published 4 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →